CAS 134381-21-8|Epoxomicin
| Common Name | Epoxomicin | ||
|---|---|---|---|
| CAS Number | 134381-21-8 | Molecular Weight | 554.719 |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 795.7±60.0 °C at 760 mmHg |
| Molecular Formula | C28H50N4O7 | Melting Point | 107-109ºC |
| MSDS | ChineseUSA | Flash Point | 435.0±32.9 °C |
Names
| Name | Epoxomicin |
|---|---|
| Synonym | More Synonyms |
Epoxomicin BiologicalActivity
| Description | Epoxomicin is a cell-permeable and irreversible proteasome inhibitor, primarily the chymotrypsin-like activity. |
|---|---|
| Related Catalog | Signaling Pathways >>Metabolic Enzyme/Protease >>ProteasomeResearch Areas >>CancerNatural Products >>Others |
| References | [1]. Kim KB, et al. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: insights into specificity and potency. Bioorg Med Chem Lett. 1999 Dec 6;9(23):3335-40. [2]. Hanada M, et al. Epoxomicin, a new antitumor agent of microbial origin. J Antibiot (Tokyo). 1992 Nov;45(11):1746-52. [3]. Garrett IR, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest. 2003 Jun;111(11):1771-82. [4]. McNaught KS, et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol. 2004 Jul;56(1):149-62. [5]. Rideout HJ, et al. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP70, following proteasomal inhibition. J Neurochem. 2005 Jun;93(5):1304-13. |
Chemical & Physical Properties
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 795.7±60.0 °C at 760 mmHg |
| Melting Point | 107-109ºC |
| Molecular Formula | C28H50N4O7 |
| Molecular Weight | 554.719 |
| Flash Point | 435.0±32.9 °C |
| Exact Mass | 554.367920 |
| PSA | 157.44000 |
| LogP | 3.32 |
| Vapour Pressure | 0.0±6.3 mmHg at 25°C |
| Index of Refraction | 1.504 |
| InChIKey | DOGIDQKFVLKMLQ-JTHVHQAWSA-N |
| SMILES | CCC(C)C(NC(=O)C(C(C)CC)N(C)C(C)=O)C(=O)NC(C(=O)NC(CC(C)C)C(=O)C1(C)CO1)C(C)O |
| Storage condition | -20°C |
Safety Information
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
Articles13
More Articles| Intramitochondrial adenylyl cyclase controls the turnover of nuclear-encoded subunits and activity of mammalian complex I of the respiratory chain. Biochim. Biophys. Acta 1853(1) , 183-91, (2015) In mammalian cells the nuclear-encoded subunits of complex I are imported into mitochondria, where they are assembled with mt-DNA encoded subunits in the complex, or exchanged with pre-existing copies... | |
| Ataxia telangiectasia mutated (ATM) inhibition transforms human mammary gland epithelial cells. J. Biol. Chem. 285 , 13092-106, (2010) Carriers of mutations in the cell cycle checkpoint protein kinase ataxia telangiectasia mutated (ATM), which represent 1-2% of the general population, have an increased risk of breast cancer. However,... | |
| The ubiquitin-proteasome system regulates the stability and activity of the glucose sensor glucokinase in pancreatic β-cells. Biochem. J. 456(2) , 173-84, (2013) The ubiquitin-proteasome system is important to maintain pancreatic β-cell function. Inhibition of the proteasome significantly reduced glucose-induced insulin secretion. Key regulators of the stimulu... |
Synonyms
| S7038,BU-4061T |
| Epoxomicin (BU-4061T) |
| (2S,3S)-2-[[(2S,3S)-2-[acetyl(methyl)amino]-3-methylpentanoyl]amino]-N-[(2S,3R)-3-hydroxy-2-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]butanoyl]-3-methylpentanamide |
| Epoxomicin |
| N-Acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyl-2-oxiranyl]-1-oxo-2-pentanyl}-L-threoninamide |
| L-Threoninamide, N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-[(1S)-3-methyl-1-[[(2R)-2-methyloxiranyl]carbonyl]butyl]- |
